Sinovac’s COVID vaccine highly effective against serious illness – study in Malaysia


A health worker administers the Sinovac coronavirus disease (COVID-19) vaccine to an elderly man at his home in Sabak Bernam, Malaysia, July 1, 2021. REUTERS / Lim Huey Teng

KUALA LUMPUR, Sept. 24 (Reuters) – Sinovac’s COVID-19 vaccine (SVA.O) is highly effective against serious illness, although rival shots from Pfizer / BioNTech and AstraZeneca have shown better rates of protection, has shown a great study of the real world in Malaysia.

The latest data is a boost to the Chinese company, whose COVID-19 vaccine is under increasing scrutiny for its effectiveness following reports of infections among healthcare workers fully immunized with the Sinovac vaccine in Indonesia and Thailand. Read more

The study, conducted by the Malaysian government, found that 0.011% of the estimated 7.2 million Sinovac vaccine recipients required treatment in intensive care units (ICUs) for COVID-19 infections, the officials told Thursday. journalists from health officials.

In contrast, 0.002% of the approximately 6.5 million Pfizer (PFE.N) / BioNTech (22UAy.DE) vaccine recipients required intensive care treatment for COVID-19 infections, while 0.001% of 744,958 AstraZeneca (AZN.L) vaccine recipients required similar treatment.

Kalaiarasu Peariasamy, director of the Clinical Research Institute that conducted the study with a national COVID-19 task force, said vaccinations – regardless of brand – reduced the risk of ICU admission for 83% and the risk of death. 88% based on a smaller study of around 1.26 million people.

“The breakthrough rate for intensive care unit admissions is extremely low,” he said, adding that the overall intensive care admissions among those fully vaccinated stood at 0.0066%.

The death rate of fully vaccinated people was also low at 0.01% and the majority of them were over 60 years of age or had co-morbidities.

There were differences in the demographics of recipients of the three vaccines and that could have led to different results, Kalaiarasu said.

Many AstraZeneca beneficiaries were “in adulthood,” while the injections from Pfizer and Sinovac were “very much aimed at the vulnerable population,” he said.

AstraZeneca beneficiaries also represented a much smaller proportion of the study, which involved around 14.5 million people fully vaccinated and conducted for more than five months since April 1.

In July, Malaysia announced that it would stop administering the Sinovac vaccine once its supplies were completed because it had a sufficient number of other vaccines for its program. Read more

The Sinovac vaccine has been widely used in several countries, including China, Indonesia, Thailand and Brazil, and the company said earlier this month that it has provided 1.8 billion doses to the country and the foreigner.

Malaysia has fully immunized 58.7% of its 32 million population and administered at least one dose to 68.8%.

Reporting by Liz Lee, written by A. Ananthalakshmi; Editing by Miyoung Kim and Michael Perry

Our Standards: Thomson Reuters Trust Principles.


Leave A Reply